胸腺五肽治疗伴并发症肺结核效果观察  

The efficacy of thymopentin on tuberculosis with complications

作　　者：刘士甫[1] 张鑫[1] 赵磊[1] 康书慧[1] 曹金凤[1] 高伟[1] 

机构地区：[1]石家庄市第五医院结核科,石家庄056000

出　　处：《中国医学前沿杂志（电子版）》2015年第6期133-135,共3页Chinese Journal of the Frontiers of Medical Science(Electronic Version)

摘　　要：目的探讨胸腺五肽治疗伴并发症肺结核的临床效果和安全性。方法选取2013年3月至2014年1月本院收治的伴并发症肺结核患者120例为研究对象,将其按照完全随机方法分为对照组(60例)和研究组(60例)。对照组患者给予抗结核基础治疗,研究组患者给予胸腺五肽+抗结核基础治疗。观察两组患者治疗后第1、2、3个月的临床效果和不良反应发生情况。结果对照组患者治疗后第1、2、3个月治疗总有效率分别为48.3%、61.7%、73.3%,研究组分别为60.0%、75.0%、83.3%,两组比较差异具有显著性(P<0.05)。对照组患者治疗后第1、2、3个月不良反应发生率分别为48.3%、71.7%、60.0%,研究组分别为21.7%、23.3%、13.3%,两组比较差异具有显著性(P<0.05)。结论胸腺五肽能够明显提高伴并发症肺结核患者的临床疗效,减少不良反应的发生,安全性高,值得临床推广。ObjectiveTo explore the efifcacy of thymopentin on tuberculosis with complications.Method 120 patients with consecutive tuberculosis were enrolled from March 2013 to January 2014 in our hospital, 60 cases were randomly assigned to research group and 60 cases to control group. Research group patients were treated with thymopentin＋basis of anti-tuberculosis treatment, control group patients were treated with basis of anti-tuberculosis treatment. Clinical efifcacy and safety between the two groups were observed after 1, 2 and 3 months respectively.ResultThe total effective rate was 48.3%, 61.7%, 73.3% in control group at 1, 2 and 3 months, while which in research group was 60.0%, 75.0% 83.3%; respectively, there was signiifcant differences between the two groups （P〈0.05）. The adverse reaction rate was 48.3%, 71.7%, 60.0% in control group at 1, 2 and 3 months, while which in research group was 21.7%, 23.3%, 13.3% respectively, there was signiifcant differences between the two groups （P〈0.05）.ConclusionThymopentin can obviously improve the clinical curative effect on tuberculosis with complications and reduce the occurrence of adverse reactions, which is safety and worth of popularizing.

关 键 词：胸腺五肽 并发症 肺结核 临床疗效 

分 类 号：R521[医药卫生—内科学]